Dechert LLP Represents Onconova as it Announces Pricing of Initial Public Offering

Dechert LLP announced today that it advised Onconova Therapeutics, Inc. in an initial public offering of 5,166,667 shares of its common stock. The offering was announced today at $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Onconova. In addition, Onconova has granted the underwriters a 30-day option to purchase up to an additional 775,000 shares of common stock at the same price to cover over-allotments, if any. The shares are now trading on The NASDAQ Global Market under the ticker symbol “ONTX.” The offering is expected to close on July 30, 2013, subject to customary closing conditions.

More >>

Tags:  Dechert LLP

Patton Boggs Advises Intezyne Technologies in Acquisition of Niiki Pharma

An M&A team from Patton Boggs LLP headed by Geoff Davis, a partner in the firm’s Washington DC office and Mark Goldschmidt, a partner in the firm’s Denver office recently represented Intezyne Technologies, a leader in the use of nanotechnology in the development of cancer treatment, in its strategic acquisition of target Niiki Pharma, significantly expanding Intezyne’s portfolio of cancer drugs and market valuation.

More >>

Tags:  Squire Patton Boggs